Late response to anti-TNF-alpha therapy in refractory mucocutaneous lesions of Beh double dagger et`s disease


Autoria(s): AIKAWA, Nadia Emi; GONCALVES, Carla; SILVA, Clovis Artur Almeida; GONCALVES, Celio; BONFA, Eloisa; CARVALHO, Jozelio Freire de
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2011

Resumo

Beh double dagger et`s disease (BD) is a multisystem chronic inflammatory disorder characterized by oral and genital ulceration and ocular involvement. Recurrent oral and genital ulcers are the most common symptoms of BD and occur in more than 80% of patients. The treatments of these disease manifestations include colchicine, corticosteroids and immunosuppressive drugs in severe cases. Anti-TNF-alpha therapy may be useful in refractory severe BD, particularly for ocular, central nervous system, gastrointestinal and refractory mucocutaneous lesions. During a 2-year period, 280 patients suffering from rheumatic diseases received anti-TNF-alpha agents at the infusion center of our University Hospital. Two patients (0.7%) presented BD; one of them had celiac disease as well, with recalcitrant mucocutaneous lesions that were not responsive to immunosuppressive drugs. We reported those patients who were successfully treated with infliximab and adalimumab, despite their late response.

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, FAPESP[06/61303-7]

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, CNPQ[300248/2008-3]

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, CNPQ[305468/2006-5]

Federico Foundation

Identificador

RHEUMATOLOGY INTERNATIONAL, v.31, n.8, p.1097-1099, 2011

0172-8172

http://producao.usp.br/handle/BDPI/21712

10.1007/s00296-009-1276-x

http://dx.doi.org/10.1007/s00296-009-1276-x

Idioma(s)

eng

Publicador

SPRINGER HEIDELBERG

Relação

Rheumatology International

Direitos

restrictedAccess

Copyright SPRINGER HEIDELBERG

Palavras-Chave #Behcet`s disease #Celiac disease #Anti-TNF-alpha #Oral ulcers #Genital ulcers #Cutaneous lesions #BEHCETS-DISEASE #INFLIXIMAB #ETANERCEPT #ADALIMUMAB #REMISSION #EFFICACY #CRITERIA #Rheumatology
Tipo

article

original article

publishedVersion